Peptide LibraryChonluten
Also known as: Lung bioregulator, EDG, T-34
Chonluten (also called Lung bioregulator or EDG) is a khavinson lung bioregulator. Chonluten is Glu-Asp-Gly, a synthetic tripeptide in the Khavinson series associated with bronchial epithelium and lung tissue. The proposed mechanism follows the series hypothesis: short peptides entering the nucleus and interacting with promoter regions to modulate transcription of tissue-relevant genes.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Bronchial epithelium (proposed)
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 3
- Listed offers
- 3
- Price per mg
- $2.50–$3.50/mg
Research summary
Glu-Asp-Gly, a synthetic tripeptide in the Khavinson bioregulator series, sold as a bronchial and lung bioregulator. The proposed tissue-specific activity rests on older Russian-language cytogenetic work that has not been independently replicated, and no receptor or signalling pathway has been characterised. There is no modern randomised trial evidence for respiratory outcomes, and it is not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Chonluten profile summarises 1 cited study listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Chonluten dosage: no established human dose
Chonluten has no established human dosage. It is the synthetic tripeptide Glu-Asp-Gly (EDG), sold as a lung and bronchial bioregulator. No human or animal study of it is indexed in PubMed, and no trial is registered on ClinicalTrials.gov; the one indexed study is in a human cell line.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Chonluten (Glu-Asp-Gly) is a short synthetic peptide in the Khavinson series, linked to bronchial tissue. Its one indexed study is an anti-inflammatory cell-culture experiment; no study has given it to an animal or a person. Nothing here establishes a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| In vitro — five Khavinson peptides in THP-1 monocytes and macrophages (2022)Preclinical · Cell-culture study (Italian and Russian authors, including the group that developed the peptide) | Human THP-1 monocytic leukaemia cells and macrophages derived from them | Not stated in the indexed abstract; added to cell culture, not given to an organism | In vitro, added to culture | — | — | Chonluten lowered TNF release from monocytes exposed to bacterial lipopolysaccharide; all five peptides lowered TNF and IL-6 in macrophages and reduced cell adhesion | Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022. |
Where sources disagree
- No indexed study or registered trial reports a dose of Chonluten, so protocols given for it have no verifiable primary source.
- Chonluten and Bronchogen (Ala-Glu-Asp-Leu) are both sold for the lungs but are different peptides with separate literature.
Reconstitution
Common research vial sizes: 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
| 20 mg | 4 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Chonluten is Glu-Asp-Gly, a synthetic tripeptide in the Khavinson series associated with bronchial epithelium and lung tissue. The proposed mechanism follows the series hypothesis: short peptides entering the nucleus and interacting with promoter regions to modulate transcription of tissue-relevant genes. Reported findings concern normalisation of bronchial epithelial gene expression in older Russian-language cytogenetic work. There is no independent replication, no characterised receptor or signalling cascade, and no modern randomised controlled trial evidence for the claimed pulmonary effects.
Origin
Synthetic short peptide bioregulator.
Targets
Research statistics
1 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Chonluten is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Chonluten side effects
Chonluten has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Chonluten: frequently asked questions
What is Chonluten?
Glu-Asp-Gly, a synthetic tripeptide in the Khavinson bioregulator series, sold as a bronchial and lung bioregulator. The proposed tissue-specific activity rests on older Russian-language cytogenetic work that has not been independently replicated, and no receptor or signalling pathway has been characterised. There is no modern randomised trial evidence for respiratory outcomes, and it is not FDA-approved.
How does Chonluten work?
Chonluten is Glu-Asp-Gly, a synthetic tripeptide in the Khavinson series associated with bronchial epithelium and lung tissue. The proposed mechanism follows the series hypothesis: short peptides entering the nucleus and interacting with promoter regions to modulate transcription of tissue-relevant genes.
Is Chonluten FDA approved?
No. Chonluten is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Chonluten?
Compounds most often compared with Chonluten include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Chonluten profile is compiled from published literature (1 cited study linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Chonluten research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →